Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited metabolic disorder caused by an enzyme deficiency, resulting in an inability to oxidize fatty acids for energy production.
No HPO annotations are available for this condition.
Age of onset: infancy, before birth, newborn period.
Lipoid proteinosis (LP) is characterized by deposition of hyaline-like material that results in a hoarse voice from early infancy and characteristic skin lesions. To date, more than 400 individuals have been identified with biallelic pathogenic variants in ECM1 . The following description of the phenotypic features associated with this condition is based on these reports. Table 2. Lipoid Proteinosis: Frequency of Select Features Feature | Frequency
Lipoid proteinosis (LP), which is characterized by deposition of hyaline-like material in the larynx, oral cavity, skin, and internal organs, should be suspected in individuals with the following clinical manifestations, neuroimaging findings and family history. Clinical manifestations (in order of their importance for diagnosis):
Source: GeneReviews — "Lipoid Proteinosis"
No approved treatments are currently available for inherited lipid metabolism disorder. The disease remains an area of unmet medical need.
No clinical practice guidelines for lipoid proteinosis (LP) have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with LP, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Lipoid Proteinosis (LP)
Table 6.
Recommended Surveillance for Individuals with Lipoid Proteinosis (LP)
System/Concern | Evaluation | Frequency
| Otolaryngologist assessment of airway vocal cords | Every 6 mos
Cutaneous papules
plaques | Dermatologic exams
163 clinical trials registered, 33 recruiting. Interventions under study include other interventions, drug therapy, medical devices, and procedural interventions. Pipeline includes 11 PHASE4, 9 PHASE3, 8 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT06494488](https://clinicaltrials.gov/study/NCT06494488) |
Data assembled from 5 of 12 sources · Last updated Nov 17, 2026, 10:39 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
In nearly all | Common | Infrequent |
|---|---|---|
Hoarse voice | Severe dysphonia /or complete aphonia | Breathing difficulties |
Moniliform blepharosis | Hyperkeratotic verrucous lesions | Patchy diffuse alopecia |
Source: GeneReviews — "Lipoid Proteinosis"
Table 3.
Genes and Disorders of Interest in the Differential Diagnosis of Lipoid Proteinosis
Gene | Disorder | MOI | Overlapping Features | Distinguishing Features
| Pseudoxanthoma elasticum (PXE) | AR | Some skin changes in LP (e.g., yellowish papules seen on the neck) are reminiscent of those in PXE. | Ocular manifestations are different:
LP is characterized by moniliform blepharosis.
PXE is characterized by subretinal neovascularization w/hemorrhage that can cause significant visual impairment.
FECH | Autosomal recessive erythropoietic protoporphyria (EPP) | AR | The early vesicular lesions in LP can resemble those in EPP. |
Source: GeneReviews — "Lipoid Proteinosis"
Biomarker and diagnostic research for inherited lipid metabolism disorder has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Skin lesions | Dermatologist | Assess for hemorrhagic or crusting lesions. |
Upper airway | Otolaryngologist | Assess for airway obstruction assoc w/vocal cord infiltration. |
Epilepsy | Neurologist | If clinical findings suggest seizures Neuropsychiatric |
disorders | Neurobehavioral testing | Assess for memory impairment, hallucinations, paranoia, aggressive behavior. Brain MRI |
counseling | By genetics professionals1 | To inform patients families re nature, MOI, implications of LP in order to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Lipoid Proteinosis (LP) Manifestation/Concern | Treatment | Considerations/Other |
Airway obstruction | Microlaryngoscopic excision of laryngeal deposits | Improves airway access voice quality Tracheostomy |
plaques | Oral dimethylsulfoxide, D-penicillamine, oral retinoid (e.g., acitretin) | For skin softening concomitant amelioration of mucosal lesions hoarseness |
Seizures | ASM as determined by neurologist | Some persons are resistant to ASMs.; Successful treatment w/ASMs incl Tegretol® Keppra® has been reported . ASM = anti-seizure medication Surveillance Table 6. |
Recommended Surveillance for Individuals with Lipoid Proteinosis (LP) System/Concern | Evaluation | Frequency |
Airway obstruction | Otolaryngologist assessment of airway vocal cords | Every 6 mos Cutaneous papules plaques |
Seizures | Neurologic eval | Annually Neuropsychiatric disorders |
Source: GeneReviews — "Lipoid Proteinosis"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Lipoid Proteinosis"
163 trials found
| Neurologic eval | Annually
Neuropsychiatric
disorders | Monitor for emotional cognitive development.
Source: GeneReviews — "Lipoid Proteinosis"
Differential Thrombogenesis by EPA and DHA Mediated by HDL |
EARLY_PHASE1 |
The Miriam Hospital |
RECRUITING |
[NCT05693701](https://clinicaltrials.gov/study/NCT05693701) | Multicomponent Intervention Study- Blood Donors With High Cholesterol | NA | University of Texas Southwestern Medical Center | RECRUITING |
[NCT07359105](https://clinicaltrials.gov/study/NCT07359105) | Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) | NA | Sin Gon Kim | RECRUITING |
[NCT06382298](https://clinicaltrials.gov/study/NCT06382298) | Cottonseed Oil Versus Matched PUFA Effects | NA | University of Georgia | RECRUITING |
[NCT06797401](https://clinicaltrials.gov/study/NCT06797401) | Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia | PHASE2 | Ribocure Pharmaceuticals AB | RECRUITING |
500 publications have been identified in PubMed for inherited lipid metabolism disorder. Research spans Review / Meta-Analysis (37%), Epidemiology / Natural History (18%), and Basic Science / Preclinical (17%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 186 | 37% |
Disease patterns and progression | 88 | 18% |
Laboratory research | 83 | 17% |
Patient case studies | 55 | 11% |
Clinical study results | 28 | 6% |
Testing and diagnosis research | 27 | 5% |
New treatment approaches | 18 | 4% |
Other research | 15 | 3% |
Nguyen DT (2027). [PMID: 42805283](https://pubmed.ncbi.nlm.nih.gov/42805283/). *Bone*. [Epidemiology / Natural History]
Ping L (2027). [PMID: 42486458](https://pubmed.ncbi.nlm.nih.gov/42486458/). *J Ethnopharmacol*. [Epidemiology / Natural History]
Terada R (2026). [PMID: 42843896](https://pubmed.ncbi.nlm.nih.gov/42843896/). *Xenobiotica*. [Epidemiology / Natural History]
Soran H (2026). [PMID: 42319369](https://pubmed.ncbi.nlm.nih.gov/42319369/). *J Comp Eff Res*. [Clinical Trial Publication]
Karaskova E (2026). [PMID: 42404342](https://pubmed.ncbi.nlm.nih.gov/42404342/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Shapiro MD (2026). [PMID: 42153685](https://pubmed.ncbi.nlm.nih.gov/42153685/). *J Am Coll Cardiol*. [Review / Meta-Analysis]
Wang Y (2026). [PMID: 41710433](https://pubmed.ncbi.nlm.nih.gov/41710433/). *J Sports Sci Med*. [Epidemiology / Natural History]
Ikhile D (2026). [PMID: 42044653](https://pubmed.ncbi.nlm.nih.gov/42044653/). *Lancet Diabetes Endocrinol*. [Review / Meta-Analysis]
Fanaropoulou NM (2026). [PMID: 42914050](https://pubmed.ncbi.nlm.nih.gov/42914050/). *Am J Med Sci*. [Review / Meta-Analysis]
Wu SF (2026). [PMID: 41691973](https://pubmed.ncbi.nlm.nih.gov/41691973/). *J Chromatogr B Analyt Technol Biomed Life Sci*. [Case Report / Case Series]
AI-curated news mentioning inherited lipid metabolism disorder
Updated Nov 11, 2026
ocular manifestations of lipid disorders clinical clues for lipidologists narrative review